how much retatrutide to start VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Research Concentration Overview |
Description
Its one of the more comprehensive portals weve used across GLP-1 clinics
doi: 10.1159/000478872 12 SisleySGutierrez-AguilarRScottMD'AlessioDASandovalDASeeleyRJ
doi: 10.1161/CIRCULATIONAHA.125.074545 Summary Keywords cardiovascular outcomes, SGLT2 inhibitors, GLP-1 agonists, combination therapy, heart failure, renal outcomes Citation Aristizbal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, Lpez-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condoy JS, Ortiz-Prado E, Rico-Fontalvo J, Gmez-Mesa J-E, Abreu-Lomba A and Rivera-Martnez W-A (2025) A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists a comprehensive review
ArticlePubMedPMC 66
For that reason, many of these medications are FDA-approved and indicated for diabetes treatment
Mack I, lschlger S, Sauer H, von Feilitzsch M, Weimer K, Junne F, et al
